While these pathways have been described as potential targets for treament of sarcomas, not all patients may respond to such approaches, as, for example, was recently shown for treatment with a CTLA4 inhibitor in synovial sarcoma (48). This evidence concerns the gene CTLA4 and synovial sarcoma.